UA113215C2 - Похідні проліків (e)-n-метил-n-((3-метилбензофуран-2-іл)метил)-3-(7-оксо-5,6,7,8-тетрагідро-1,8-нафтиридин-3-іл)акриламіду - Google Patents

Похідні проліків (e)-n-метил-n-((3-метилбензофуран-2-іл)метил)-3-(7-оксо-5,6,7,8-тетрагідро-1,8-нафтиридин-3-іл)акриламіду

Info

Publication number
UA113215C2
UA113215C2 UAA201500343A UAA201500343A UA113215C2 UA 113215 C2 UA113215 C2 UA 113215C2 UA A201500343 A UAA201500343 A UA A201500343A UA A201500343 A UAA201500343 A UA A201500343A UA 113215 C2 UA113215 C2 UA 113215C2
Authority
UA
Ukraine
Prior art keywords
methyl
methylbenzofuran
derivatives
acrylamide
compounds
Prior art date
Application number
UAA201500343A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UA113215C2 publication Critical patent/UA113215C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Винахід стосується похідних (Е)-N-метил-N-((3-метилбензофуран-2-іл)метил)-3-(7-оксо-5,6,7,8-тетрагідро-1,8-нафтиридин-3-іл)акриламідної сполуки із значною розчинністю, стабільністю в твердому стані і біодоступністю. Було виявлено, що вказані сполуки є ефективними інгібіторами FabI. Крім того, показано, що певні сполуки були стабільними щодо впливу радіаційної стерилізації, і, таким чином, добре підходять для виробництва стерильного препарату для використання в лікуванні захворювань, викликаних бактеріальними інфекціями.
UAA201500343A 2012-06-19 2013-06-19 Похідні проліків (e)-n-метил-n-((3-метилбензофуран-2-іл)метил)-3-(7-оксо-5,6,7,8-тетрагідро-1,8-нафтиридин-3-іл)акриламіду UA113215C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661559P 2012-06-19 2012-06-19
PCT/IB2013/001780 WO2013190384A1 (en) 2012-06-19 2013-06-19 Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide

Publications (1)

Publication Number Publication Date
UA113215C2 true UA113215C2 (xx) 2016-12-26

Family

ID=49768192

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201500343A UA113215C2 (xx) 2012-06-19 2013-06-19 Похідні проліків (e)-n-метил-n-((3-метилбензофуран-2-іл)метил)-3-(7-оксо-5,6,7,8-тетрагідро-1,8-нафтиридин-3-іл)акриламіду

Country Status (34)

Country Link
US (2) US8901105B2 (uk)
EP (1) EP2861608B8 (uk)
JP (2) JP6085026B2 (uk)
KR (1) KR101720885B1 (uk)
CN (1) CN104684922B (uk)
AU (1) AU2013279021C1 (uk)
BR (2) BR122021020778B1 (uk)
CA (1) CA2875916C (uk)
CL (1) CL2014003472A1 (uk)
CY (1) CY1122006T1 (uk)
DK (1) DK2861608T3 (uk)
EA (1) EA028136B1 (uk)
ES (1) ES2731474T3 (uk)
HK (1) HK1208226A1 (uk)
HR (1) HRP20190980T1 (uk)
HU (1) HUE043836T2 (uk)
IL (1) IL236066A (uk)
IN (1) IN2014KN02915A (uk)
LT (1) LT2861608T (uk)
MA (1) MA37625B1 (uk)
ME (1) ME03392B (uk)
MX (1) MX356695B (uk)
MY (1) MY170437A (uk)
NZ (1) NZ702695A (uk)
PH (1) PH12014502823A1 (uk)
PL (1) PL2861608T3 (uk)
PT (1) PT2861608T (uk)
RS (1) RS58898B1 (uk)
SG (1) SG11201408100YA (uk)
SI (1) SI2861608T1 (uk)
TN (1) TN2014000506A1 (uk)
TR (1) TR201909016T4 (uk)
UA (1) UA113215C2 (uk)
WO (1) WO2013190384A1 (uk)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
WO2013190384A1 (en) 2012-06-19 2013-12-27 Affinium Pharmaceuticals, Inc. Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
CN108778286A (zh) * 2016-02-26 2018-11-09 德彪药业国际股份公司 用于治疗糖尿病足感染的药物
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
PL3474820T3 (pl) 2017-08-24 2024-05-13 Novo Nordisk A/S Kompozycje glp-1 i ich zastosowania
US11691967B2 (en) 2018-03-12 2023-07-04 The Board Of Trustees Of The University Of Illinois Antibiotics effective for gram-negative pathogens
WO2020099341A1 (en) * 2018-11-12 2020-05-22 Debiopharm International S.A. Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
SG11202106061VA (en) 2018-12-21 2021-07-29 Acurx Pharmaceuticals Llc Dna polymerase iiic inhibitors and use thereof
RS64158B1 (sr) 2019-02-14 2023-05-31 Debiopharm Int Sa Formulacija afabicina, postupak za njenu proizvodnju
CN113939306B (zh) * 2019-06-14 2024-07-19 德彪药业国际股份公司 用于治疗涉及生物膜的细菌感染的药物及其用途
IL293980A (en) 2019-12-19 2022-08-01 Debiopharm Int Sa New compounds and their use
TW202140063A (zh) 2020-02-18 2021-11-01 丹麥商諾佛 儂迪克股份有限公司 醫藥配方
JP2024526138A (ja) 2021-06-23 2024-07-17 デバイオファーム インターナショナル エス．エー． 新規な化合物及びその使用

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3828068A (en) 1971-05-10 1974-08-06 Tenneco Chem ((substituted indazolyl)-n1-methyl)carbamates
US4154943A (en) 1977-12-29 1979-05-15 University Of Vermont Preparation of vincadifformine
FR2619111B1 (fr) 1987-08-07 1991-01-11 Synthelabo Derives de (piperidinyl-4)methyl-2 tetrahydro-1,2,3,4 9h-pyrido (3,4-b) indole, leur preparation et leur application en therapeutique
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
DE4126662A1 (de) 1991-08-13 1993-02-18 Boehringer Mannheim Gmbh Neue 3,5-di-tert.butyl-4-hydroxyphenyl-derivate, verfahren zu ihrer herstellung und arzneimittel
HU210679B (en) 1991-11-21 1995-06-28 Richter Gedeon Vegyeszet Process for producing new tetrahydro-pyrido/3,4-b/indol derivatives and pharmaceutical compositions containing the same
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5416193A (en) 1993-04-30 1995-05-16 Pfizer Inc. Coupling reagent and method
MA23420A1 (fr) 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
US5614551A (en) 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
HUT76344A (en) 1994-06-29 1997-08-28 Smithkline Beecham Corp Vitronectin receptor antagonists
US6176842B1 (en) 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US5989832A (en) 1995-04-21 1999-11-23 Microcide Pharmaceuticals, Inc. Method for screening for non-tetracycline efflux pump inhibitors
RU2183212C2 (ru) 1995-05-11 2002-06-10 Биохеми Гезельшафт Мбх Антибактериальные цефалоспорины, фармацевтическая композиция на их основе и способ лечения
US6057291A (en) 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
KR20040058360A (ko) 1996-02-29 2004-07-03 후지사와 야꾸힝 고교 가부시키가이샤 합성 감미료
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6367985B1 (en) 1996-03-12 2002-04-09 Intellectual Property Company Optical connector using large diameter alignment features
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6995254B1 (en) 1996-08-28 2006-02-07 Affinium Pharmaceuticals, Inc. Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB I
US6294669B1 (en) 1996-09-20 2001-09-25 Meiji Seika Kaisha Ltd. Crystalline substance of cefditoren pivoxyl and the production of the same
US6521408B1 (en) 1997-09-25 2003-02-18 National Institute Of Agrobiological Sciences Method for assessing a function of a gene
DE19641437A1 (de) 1996-10-08 1998-04-09 Basf Ag 1,3-Bis-(N-lactamyl)propane und deren pharmazeutische und kosmetische Verwendung
DE19652239A1 (de) 1996-12-16 1998-06-18 Bayer Ag Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
SI9600371B (sl) 1996-12-18 2005-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Etilidenski derivati tricikličnih karbapenemov
CA2282593A1 (en) 1997-03-31 1998-10-08 Du Pont Pharmaceuticals Company Indazoles of cyclic ureas useful as hiv protease inhibitors
SI0971735T1 (sl) 1997-04-01 2008-08-31 Borody Thomas J Postopek in sestavina za zdravljenje bolezni vnetja debelega äśrevesa
US6406880B1 (en) 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
US6207679B1 (en) 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
CA2294453A1 (en) 1997-06-23 1998-12-30 Fumihiro Hirayama Prophylactic or therapeutic agent for diseases attributable to infection with helicobacters
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US6198000B1 (en) 1997-07-07 2001-03-06 Pfizer Inc. Intermediates useful in the synthesis of quinoline antibiotics
CA2298480A1 (en) 1997-07-25 1999-02-04 Tsumura & Co. Pyridylacrylamide derivatives and nephritis remedies and tgf-.beta. inhibitors containing the same
HN1998000106A (es) 1997-08-01 1999-01-08 Pfizer Prod Inc Composiciones parenterales de alatroflaxacino
US5932743A (en) 1997-08-21 1999-08-03 American Home Products Corporation Methods for the solid phase synthesis of substituted indole compounds
GB9717804D0 (en) 1997-08-22 1997-10-29 Zeneca Ltd Chemical compounds
US6432444B1 (en) 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
RU2224024C2 (ru) 1997-10-31 2004-02-20 Зингента Партисипейшнс Аг Трансгенные растения
CA2309121A1 (en) 1997-11-07 1999-05-20 Schering Corporation Phenyl-alkyl-imidazoles as h3 receptor antagonists
SE9704404D0 (sv) 1997-11-28 1997-11-28 Astra Ab New compounds
GB9725244D0 (en) 1997-11-29 1998-01-28 Zeneca Ltd Chemical compounds
DE19753298A1 (de) 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
NZ505871A (en) 1998-01-07 2002-10-25 Meiji Seika Kaisha Powdered compositions, each solid particle formed of a homogeneous mixture of Cefditoren pivoxil and a water-soluble high-molecular weight additive
US6184380B1 (en) 1999-01-25 2001-02-06 Pfizer Inc. Process for preparing naphthyridones and intermediates
US6248343B1 (en) 1998-01-20 2001-06-19 Ethicon, Inc. Therapeutic antimicrobial compositions
PA8466701A1 (es) 1998-01-21 2000-09-29 Pfizer Prod Inc Comprimido de mesilato de trovafloxacino
US6204279B1 (en) 1998-06-03 2001-03-20 Microcide Pharmaceuticals, Inc. Peptidomimetic efflux pump inhibitors
RU2241489C2 (ru) 1998-02-27 2004-12-10 Биора Биоэкс Аб Композиции матриксных протеинов для залечивания ран
US6350738B1 (en) 1998-03-06 2002-02-26 Brigham Young University Steroid derived antibiotics
US6369049B1 (en) 1998-04-30 2002-04-09 Eli Lilly And Company Treatment of mastitis
DE19820801A1 (de) 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
DE19821039A1 (de) 1998-05-11 1999-11-18 Bayer Ag Verfahren zur Herstellung von (S,S)-Benzyl-2,8-diazabicyclo[4.3.0]nonan
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6428579B1 (en) 1998-07-01 2002-08-06 Brown University Research Foundation Implantable prosthetic devices coated with bioactive molecules
US6423741B1 (en) 1998-07-10 2002-07-23 Council Of Scientific And Industrial Research Anti-microbial composition and method for producing the same
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
ATE386546T1 (de) 1998-08-04 2008-03-15 Takeda Schering Plough Animal Stabilisierte ölige zubereitung von tobicillin (beta-lactam-antibiotika)
WO2000010570A1 (fr) 1998-08-21 2000-03-02 Senju Pharmaceutical Co., Ltd. Preparations liquides aqueuses
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6518487B1 (en) 1998-09-23 2003-02-11 Pioneer Hi-Bred International, Inc. Cyclin D polynucleotides, polypeptides and uses thereof
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
DE19851104C2 (de) 1998-11-06 2003-04-03 Huhtamaki Forchheim Verfahren zum Herstellen eines mehrschichtigen Verbundes
TW526202B (en) 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
EP1154990B1 (en) 1999-02-18 2004-12-22 The Regents Of The University Of California Phthalamide-lanthanide complexes for use as luminescent markers
US6235728B1 (en) 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AU3615200A (en) 1999-03-03 2000-09-21 Princeton University Bacterial transglycosylases: assays for monitoring the activity using lipid ii substrate analogs and methods for discovering new antibiotics
US6495161B1 (en) 1999-03-09 2002-12-17 Vivorx, Inc. Cytoprotective biocompatible containment systems for biologically active materials and methods of making same
US6224579B1 (en) 1999-03-31 2001-05-01 The Trustees Of Columbia University In The City Of New York Triclosan and silver compound containing medical devices
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
AU4230900A (en) 1999-04-08 2000-10-23 General Hospital Corporation, The Purposeful movement of human migratory cells away from an agent source
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
US6290946B1 (en) 1999-05-13 2001-09-18 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders and antibacterial agents
US6514535B2 (en) 1999-05-21 2003-02-04 Noveon Ip Holdings Corp. Bioadhesive hydrogels with functionalized degradable crosslinks
AR024077A1 (es) 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
AR024158A1 (es) 1999-06-01 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
CO5180605A1 (es) 1999-06-23 2002-07-30 Smithkline Beecham Corp Compuestos de indol
CA2282066C (en) 1999-06-29 2010-09-07 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6346391B1 (en) 1999-07-22 2002-02-12 Trustees Of Tufts College Methods of reducing microbial resistance to drugs
CA2382670A1 (en) 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications
US6221859B1 (en) 1999-08-27 2001-04-24 Merck & Co., Inc. Carbapenem antibacterial compositions and methods of the treatment
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
ES2282134T3 (es) 1999-09-11 2007-10-16 THE PROCTER & GAMBLE COMPANY Copolimeros de polioxialquileno que contienen vehiculos liquidos fluidos.
ATE315395T1 (de) 1999-09-17 2006-02-15 Daiichi Asubio Pharma Co Ltd Pharmazeutische zusammensetzungen, die faropenem natrium und eine diamineacetat verbindung zur verbesserung der magen-darm trakt absorption enthalten
US6500463B1 (en) 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
EP1226138B1 (en) 1999-10-08 2004-12-29 Affinium Pharmaceuticals, Inc. Fab i inhibitors
EP1225894B1 (en) 1999-10-08 2006-07-05 Affinium Pharmaceuticals, Inc. Fab i inhibitors
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
EP1225895B1 (en) 1999-10-08 2005-05-04 Affinium Pharmaceuticals, Inc. Fab i inhibitors
US6503908B1 (en) 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
WO2001029035A1 (fr) 1999-10-19 2001-04-26 Sato Pharmaceutical Co., Ltd. Antimicrobiens 4-oxoquinolizine presentant des squelettes 2-pyridone en tant que structure partielle
US6951729B1 (en) 1999-10-27 2005-10-04 Affinium Pharmaceuticals, Inc. High throughput screening method for biological agents affecting fatty acid biosynthesis
TWI310688B (en) 1999-10-29 2009-06-11 Nektar Therapeutics Dry powder compositions having improved dispersivity
US6531291B1 (en) 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
US6514986B2 (en) 2000-11-22 2003-02-04 Wockhardt Limited Chiral fluoroquinolone arginine salt forms
US6656703B1 (en) 1999-12-29 2003-12-02 Millennium Pharamaceuticals, Inc. High throughput screen for inhibitors of fatty acid biosynthesis in bacteria
US6372752B1 (en) 2000-02-07 2002-04-16 Genzyme Corporation Inha inhibitors and methods of use thereof
ES2179729B1 (es) 2000-03-23 2003-12-16 Dreiman Lab Farmaceuticos S A Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
WO2001072317A1 (en) 2000-03-28 2001-10-04 Council Of Scientific And Industrial Research Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
EP1280753A1 (en) 2000-04-21 2003-02-05 Rhodia/Chirex, Inc. Process for preparation of r-1-(aryloxy)propan-2-ol
AU2001282988B2 (en) 2000-07-26 2006-01-05 Atopic Pty Ltd Methods for treating atopic disorders
DE10037029A1 (de) 2000-07-27 2002-02-28 Kugelstrahlzentrum Aachen Gmbh Verfahren und Vorrichtung zum Umformen von Strukturbauteilen
US6288239B1 (en) 2000-09-19 2001-09-11 Board Of Trustees Operating Michigan State University 5-trityloxymethyl-oxazolidinones and process for the preparation thereof
CN1233041C (zh) 2000-09-21 2005-12-21 剑桥半导体有限公司 半导体器件及其制作方法
US6821746B2 (en) 2000-10-06 2004-11-23 Affinium Pharmaceuticals, Inc. Methods of screening for FabK antagonists and agonists
US7048926B2 (en) 2000-10-06 2006-05-23 Affinium Pharmaceuticals, Inc. Methods of agonizing and antagonizing FabK
EP1332131A2 (en) 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
AU2002232558A1 (en) 2000-12-12 2002-06-24 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
US6388070B1 (en) 2001-01-05 2002-05-14 Orchid Chemicals & Pharmaceuticals Ltd. Thioester derivatives of thiazolyl acetic acid and their use in the preparation of cephalosporin compounds
US6495158B1 (en) 2001-01-19 2002-12-17 Lec Tec Corporation Acne patch
PA8539401A1 (es) 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
JP4387804B2 (ja) 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
US6503906B1 (en) 2002-02-21 2003-01-07 Ren-Jin Lee Method for optimizing ciprofloxacin treatment of anthrax-exposed patients according to the patient's characteristics
TW200306195A (en) 2002-04-02 2003-11-16 Tsumura & Co A phosphodiestrase IV inhibitor containing pyridylacrylic acid derivatives
WO2004014869A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
US7790709B2 (en) 2002-12-06 2010-09-07 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
DE602004016831D1 (de) 2003-03-17 2008-11-13 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
KR101299399B1 (ko) 2004-06-04 2013-08-22 아피늄 파마슈티컬스, 인크. 치료제, 및 그의 제조 및 사용 방법
BRPI0606318B8 (pt) 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
CN101415701A (zh) * 2005-12-05 2009-04-22 Affinium医药公司 作为fabi抑制剂的杂环丙烯酰胺化合物和抗菌剂
US20090156578A1 (en) 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
DK2078026T3 (da) 2006-11-21 2012-04-30 Rigel Pharmaceuticals Inc Prodrug-salte af 2, 4-pyrimidinediamine-forbindelser og anvendelser deraf
EP3255045A1 (en) 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
US20090012045A1 (en) 2007-06-26 2009-01-08 Rigel Pharmaceuticals, Inc. Methods of Treating Cell Proliferative Disorders
NZ597107A (en) * 2009-06-25 2013-12-20 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
NZ597108A (en) * 2009-06-25 2014-04-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds
UA108077C2 (xx) 2009-07-02 2015-03-25 Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
DK2501693T3 (en) * 2009-11-18 2014-12-08 Fab Pharma Sas Aza-heterocyclic acrylamides and their use as bactericides
CA2802107A1 (en) 2010-06-11 2011-12-15 Affinium Pharmaceuticals, Inc. Compounds for treatment of bovine mastitis
CN102675311A (zh) 2011-06-14 2012-09-19 苏春华 一种氟代丙烯酰胺的衍生物
EP2785715A1 (en) 2011-12-02 2014-10-08 Aurigene Discovery Technologies Limited Substituted pyridine derivatives as fabi inhibitors
WO2013190384A1 (en) 2012-06-19 2013-12-27 Affinium Pharmaceuticals, Inc. Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide

Also Published As

Publication number Publication date
MX356695B (es) 2018-06-11
LT2861608T (lt) 2019-07-10
DK2861608T3 (da) 2019-06-24
CA2875916A1 (en) 2013-12-27
IN2014KN02915A (uk) 2015-05-08
EA201492127A1 (ru) 2015-06-30
JP6085026B2 (ja) 2017-02-22
AU2013279021B2 (en) 2016-09-08
SG11201408100YA (en) 2015-01-29
CA2875916C (en) 2017-04-25
EP2861608B8 (en) 2019-06-19
SI2861608T1 (sl) 2019-08-30
NZ702695A (en) 2015-10-30
HK1208226A1 (en) 2016-02-26
BR122021020778B1 (pt) 2022-07-12
US8901105B2 (en) 2014-12-02
CL2014003472A1 (es) 2015-07-31
PH12014502823B1 (en) 2015-02-02
KR101720885B1 (ko) 2017-03-28
MY170437A (en) 2019-07-31
IL236066A (en) 2016-12-29
CN104684922A (zh) 2015-06-03
AU2013279021C1 (en) 2017-03-16
MA37625B1 (fr) 2017-04-28
US20140051666A1 (en) 2014-02-20
EP2861608B1 (en) 2019-04-24
PH12014502823A1 (en) 2015-02-02
US20150065415A1 (en) 2015-03-05
BR112014031635B1 (pt) 2022-01-11
US10035813B2 (en) 2018-07-31
TN2014000506A1 (en) 2016-03-30
BR112014031635A2 (pt) 2017-06-27
ME03392B (me) 2020-01-20
IL236066A0 (en) 2015-02-01
HRP20190980T1 (hr) 2019-08-23
HUE043836T2 (hu) 2019-09-30
CY1122006T1 (el) 2020-10-14
WO2013190384A1 (en) 2013-12-27
EP2861608A4 (en) 2016-01-20
EP2861608A1 (en) 2015-04-22
JP2015521617A (ja) 2015-07-30
MX2014015855A (es) 2015-03-05
TR201909016T4 (tr) 2019-07-22
JP2017105758A (ja) 2017-06-15
PT2861608T (pt) 2019-06-28
PL2861608T3 (pl) 2019-09-30
EA028136B1 (ru) 2017-10-31
RS58898B1 (sr) 2019-08-30
ES2731474T3 (es) 2019-11-15
CN104684922B (zh) 2016-10-26
KR20150023779A (ko) 2015-03-05
AU2013279021A1 (en) 2015-01-22
MA37625A1 (fr) 2016-09-30

Similar Documents

Publication Publication Date Title
UA113215C2 (xx) Похідні проліків (e)-n-метил-n-((3-метилбензофуран-2-іл)метил)-3-(7-оксо-5,6,7,8-тетрагідро-1,8-нафтиридин-3-іл)акриламіду
UY39630A (es) Inhibidores de bromodominios
CY1123637T1 (el) Αναστολεις μεθυλοτρανσφερασης αργινινης και χρησεις αυτων
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1121763T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
DOP2015000308A (es) Inhibidores de bromodominios
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
CY1118340T1 (el) Αναστολεις κινασης
UY37205A (es) Inhibidores de bromodominios
MX2015012005A (es) Inhibidores de bromodominio.
EA201490971A1 (ru) Производные урацила в качестве ингибиторов axl и c-met киназы
MX2015012431A (es) Pirrol amida como inhibidores.
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
MX2014012695A (es) Derivados de isoindolona.
BR112015022674A2 (pt) inibidores de bromodomínio
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.